Nathaniel Calloway
ntcalloway
Nathaniel Calloway is a biomedical scientist and fool since 2014. He focuses on the pharmaceutical industry across all market caps, with a special focus on clinical leads and regulatory impact.
Recent Articles by Nathaniel Calloway
Jun 12, 2014
by Nathaniel Calloway
3 Reasons to Watch Array Biopharma Inc.
Seldom are the risks or the profit potential higher than investing in small-cap biotech. Here we examine what Array Biopharma is doing that other biotech companies aren't that's getting the attention of the biggest analysts in the business.
May 28, 2014
by Nathaniel Calloway
New FDA Regulations Could Open The Market For Generics of the World's Bestselling Biologics
Its not a coincidence that a majority of the world's bestselling drugs are biologics. These new therapies gained prominence in the past decade in part because they provide increased protection against competition. The FDA hopes to change that by implementing a new fast track for approval for so called biosimilar generics.
May 27, 2014
by Nathaniel Calloway
With the Pfizer-AstraZeneca Deal Dead, Is Pfizer a Buy?
The botched merger to create the world's largest pharmaceutical company has left many with a bad taste in their mouth and Pfizer's stock depressed. Will Pfizer return to its plan to divide the company from 2013 and what would this mean for the bottom line? Is now the time to buy?
May 20, 2014
by Nathaniel Calloway
Can New CDC Guidelines Help Gilead's Growth?
After the blockbuster earnings for Gilead's new hepatitis C drug this past quarter, it's easy to forget that its HIV medication Truvada has been the historical money maker. Now the CDC is advising doctors to prescribe Truvada to anyone at risk of getting HIV, or upwards of half a million Americans.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.